KKR to buy medical device firm Integer Holdings for $5.7 billion
According to Reuters, KKR will buy Integer Holdings in an all-cash deal valued at $5.7 billion. Integer said KKR will pay $127 per share, a 4.78% premium to the prior close. Integer shares rose about 2% premarket. The deal is expected to close by year-end.
How this was made
The 30-second read
Why it matters
For ITGR, the key tradable facts are the $127 offer price, the implied 4.78% premium, and the premarket +2% reaction, implying immediate takeover-arbitrage interest. For KKR, the headline is deal size and structure, with execution risk and closing timeline as the main uncertainties.
Market read
A fresh, all-cash acquisition bid with a stated offer price and premium typically drives immediate repricing in the target and supports deal-related sentiment in the acquirer.
What to watch
Traders should monitor deal certainty drivers not covered here, including regulatory review timing, financing conditions for the all-cash offer, and any shareholder approval requirements.
Background
The article reports a new take-private style acquisition: KKR buying Integer Holdings in an all-cash transaction valued at $5.7 billion.
Ticker impact
KKR will buy Integer Holdings in an all-cash $5.7 billion deal, offering $127 per share and targeting year-end close.
Likely positive near-term sentiment for KKR, but magnitude depends on deal terms, financing, and any regulatory/closing risks not detailed here.
The article discloses deal size, structure (all-cash), and offer price, which typically supports deal-related optimism; however, it provides no financing, regulatory, or break-fee specifics.
Integer Holdings agreed to be acquired by KKR for $127 per share in an all-cash $5.7 billion transaction.
Near-term upside bias toward deal completion, with volatility around deal certainty and any competing bids.
The article provides the per-share offer ($127), implied premium (4.78%), and that shares rose 2% premarket, which are concrete, tradable takeover signals.
Market effects
Medical-device outsourcing and components M&A can re-rate perceived strategic value and consolidation expectations in the med-tech supply chain.
Limited direct regional impact beyond Plano, Texas-based Integer, but deal headlines can influence broader US med-tech M&A sentiment.
Global med-tech manufacturers rely on outsourced components; consolidation at suppliers can affect supply-chain bargaining dynamics over time.
Counterpoint
The modest 4.78% premium suggests limited competitive pressure, so deal spread could compress quickly if certainty improves, or widen if closing risks emerge.
Key entities
- acquirerKKR
Private equity firm agreeing to buy Integer Holdings in an all-cash $5.7 billion deal.
- targetInteger Holdings
Medical-device outsourcing firm agreeing to be acquired for $127 per share.
